Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.53 |
| ▸ | HTR2B | P41595 | 6/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24663868 | 1.00 | HTR2C (0.53) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL6130292 | 0.80 | HTR2C (0.57) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL6130290 | 0.80 | HTR2C (0.57) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL1600657 | 0.77 | HTR2C (0.58) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL4587814 | 0.77 | HTR2C (0.53) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL13305511 | 0.77 | HTR2C (0.58) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL22549670 | 0.73 | AKR1C3 (0.49) | FFAR1HRH3 | |
| SCHEMBL22875209 | 0.73 | EPHX2 (0.47) | HTR2CMAOBKDM1AFFAR1HRH3 | |
| SCHEMBL1797394 | 0.73 | HTR2C (0.61) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL24663869 | 0.72 | IDO1 (0.51) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | HTR2C 4250/4885HTR2B 3330/4885HTR2A 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.